Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Salveen Richter
Goldman Sachs Group, Inc., Research Division

And to start, can you provide a quick overview of where the company stands today, your strategic focus on the type 1 diabetes and in vivo CAR-T franchises and key catalysts for the second half and beyond?

Steven Harr
President, CEO & Director

Sure. Well, first off, Salveen, thank you, and thank you, Goldman Sachs, for having us. And thank you for everybody in the room and online who is joining us. Yes. So maybe just one last thing I’d say, I think you know we’ll make forward-looking statements. So please refer to our SEC — most recent SEC filing, our 10-Q for risk factors.

So take a step back. The company when we started it, we had a vision. And that vision was to try to go after and tackle what we thought were the most important challenges in making our vision a reality, which was turning this idea of engineering cells or modifying cells into medicines. And so we went after 2 different platforms and technologies. One, if you take a step back and think about almost every disease you can think of is caused by either a missing and damaged cell or a cell that’s kind of gone awry.

And so to go after missing or damaged